. 2021 Jan 12;6:15. doi: 10.1038/s41392-020-00376-4

Table 8.

Clinical trials of EBV-related therapeutic vaccines

Ref.	Conditions	Interventions	Enrollment	Clinical outcome
NCT01800071	EBV-positive NPC	MVA-EBNA1/LMP2 vaccine	22	Immune memory and recall response to MVA-EBNA1/LMP2 vaccination, Measurement of EBV genome levels
NCT01094405	EBV-positive NPC	Recombinant Epstein–Barr virus (EBV) vaccine	25	Objective Response Rate (ORR), Duration of Response (DR), Progression-free survival (PFS), Overall survival (OS)
NCT00078494	Recurrence NPC	EBV-LMP-2 peptide	99	Evaluate how the vaccines affect immune system cells
NCT00478062	After Initial Therapy of Hodgkin’s Lymphoma	Hodgkin’s antigens-GM-CSF-expressing cell vaccine	35	Determine immunologic responses
NCT01147991	EBV-positive cancers	EBNA1 C-terminal/LMP2 chimeric protein	16	To determine safety and immunologic responses
Hui et al.³⁷⁴ NCT01256853	EBV-positive NPC	MVA-EL, which encodes an EBNA1/LMP2 fusion protein	18	Toxicity of MVA-EBNA1/LMP2 vaccine, T-cell responses, and assess the changes of EBV genome
Si et al.³⁷¹	EBV-positive NPC	Recombinant adenoviral vaccine expressing EBV-LMP2 protein (rAd5-EBV-LMP2)	24	Proportion of CD3⁺ CD4⁺ cells in peripheral blood
Chia et al.³⁷²	EBV-positive NPC	DCs transduced with adenovirus encoding a truncated LMP1 (DeltaLMP1) and full-length LMP2 (Ad-DeltaLMP1-LMP2)	16	Detected in tLMP1/2-specific T cell
Lin et al.³⁷²	EBV-positive NPC	Autologous DCs pulsed with HLA-restricted epitope peptides from LMP2	16	CD8⁺ T-cell responses
Li et al.⁴⁶⁶	EBV-positive NPC	Autologous DCs pulsed with HLA-restricted epitope peptides from LMP2	16	Patients responded to LMP2A peptides Serum EBV-DNA level